(Reuters)—Eli Lilly & Co said its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year. The data come two weeks after U.S. health regulators approved the drug, baricitinib, under the trade name Olumiant, with a far more restrictive label…
U.S. Justice Department Says Obamacare Individual Mandate Unconstitutional
WASHINGTON (Reuters)—The U.S. Department of Justice (DOJ) said on Thursday that the part of Obamacare requiring individuals to have health insurance is unconstitutional, an unusual move that could lead to stripping away some of the most significant and popular parts of the law. In a brief filed in a federal court in Texas, the department…
Hip Bone Deterioration May Differ Significantly Between Men & Women
NEW YORK (Reuters Health)—Various image analysis techniques show sex-specific patterns of bone deterioration at the hip, suggesting that men and women should be assessed differently for hip fracture risk, researchers say. “One major contribution of this work is the integration of data-driven computational anatomy approaches, which showed that proximal femur fragility linked to fracture seems…
Fed Up with Rising Costs, Big U.S. Firms Dig Into Healthcare
SAN JOSE, Calif., (Reuters)—At its Silicon Valley headquarters, network gear maker Cisco Systems Inc. is going to unusual lengths to take control of the relentless increase in its U.S. healthcare costs. The company is among a handful of large American employers who are getting more deeply involved in managing their workers’ health instead of looking…
AbbVie’s RA Drug Succeeds in Late Stage Study
(Reuters)—Abbvie Inc. says its experimental drug met the main goal of halting progression of moderate to severe rheumatoid arthritis (RA) in a late-stage trial. The drug, upadacitinib, was tested as a monotherapy in patients who have not been treated with chemotherapy agent methotrexate. Upadacitinib, which belongs to a class of drugs known as JAK inhibitors,…
How Clinical Nurse Specialists Aid Rheumatology Patients
With advanced training and education, a clinical nurse specialist can be a valuable member of a patient’s healthcare team and a rheumatologist’s practice, acting as an extension of the rheumatologist to ensure a patient’s needs are met…
FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis
Denosumab is now approved to treat adults with glucocorticoid-induced osteoporosis…
The Right Load: Insights into Age-Impaired Mechanoadaptive Cortical Bone Response
Aging bones lose their ability to mechanoadapt, but new research suggests age-related adaptation failure may result from insufficient mechanical stimulus…
ACR/ARHP Visits the Hill; Drug Pricing ‘Blueprint’ Revealed
Greetings, Advocates! In my last update, I described the great news from February’s budget agreement that fixed Medicare’s payment adjustments so MIPS penalties would not include Part B drug costs, ensuring stabilization of the Medicare Part B drug system, among other successes. (Read the ACR’s press release on this topic.) I also described the Trump administration’s…
Think Globally; Act Locally: A Conversation with Luke Barré, MD, MPH
The ACR’s ability to address the big picture of rheumatologic care while focusing on individual practice and patient needs is one of the many things that attracted Luke Barré, MD, MPH, to the College early in his career. With training in both preventive medicine and rheumatology, Dr. Barré believes combined global and local views are…
- « Previous Page
- 1
- …
- 334
- 335
- 336
- 337
- 338
- …
- 816
- Next Page »